TaiRx, Inc. (TPEX: 6580)
Health Care · Biotechnology · TW
NT$13.55
-6.87% today · -45.3% 1Y
TaiRx, Inc. (TPEX: 6580) operates in the Biotechnology industry within the Health Care sector. The company is valued at $46.82M and employs 29 people.
Over the last twelve months the share price has lost 45.3%, trading between 11.95 and 25.45.
Tweenvest scores TaiRx, Inc. across four factors: quality 39/100, value 28/100, growth 100/100. Its strongest factor is growth.
6580 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $46.82M
- Revenue (TTM)
- $925.48K
- P/E
- —
- EPS
- -2.09
- Dividend yield
- —
- Beta (5Y)
- 0.37
- 52-week high
- NT$25.45
- 52-week low
- NT$11.95
- Avg volume (3M)
- —
- Shares outstanding
- 112.12M
- Employees
- 29
- Next earnings
- —
About TaiRx, Inc.
TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for cancer and other diseases. The company's clinical pipeline includes CVM-1118, an oral anti-cancer drug currently undergoing Phase II clinical trials, and Rexis, an add-on injection therapy for sepsis patients, which is in Phase III trials. In its pre-clinical stage, TaiRx is developing TRX-711 for secondary hyperparathyroidism, TRX-920 as an oral delivery formulation, and TRX-105, a molecule designed to treat and alleviate symptoms of various types of colitis. Beyond its developmental drugs, TaiRx also offers Zelnite, a medication that helps maintain patients' blood selenium levels and supports their immune systems. The company's future endeavors also involve the development of nodal diagnostic devices and innovative antibody-based drugs.
- ISIN
- TW0006580004
- Founded
- 2011
- Listed since
- Jun 21, 2017
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Werewolf Therapeutics, Inc.NasdaqCM: HOWL | $47.63M | $0.98 | +0.04% |
| Kalaris Therapeutics, Inc.NasdaqGM: KLRS | $47.61M | $2.00 | -15.25% |
| 2invest AGDB: 2INV | $47.49M | €7.68 | -3.52% |
| Norda ASAOTCNO: NORD | $47.08M | Nkr86.00 | — |
| Cytogen, Inc.KOSDAQ: A217330 | $46.75M | ₩2,695.00 | -7.86% |
| Solasia Pharma K.K.TSE: 4597 | $46.69M | ¥27.00 | -6.90% |
| OncoTherapy Science, Inc.TSE: 4564 | $46.54M | ¥18.00 | -5.26% |
| Apollomics, Inc.NasdaqCM: APLM | $46.34M | $21.10 | -1.86% |
Figures last refreshed Oct 18, 2026.